Financial Advocates Investment Management Acquires Shares of Regeneron Pharmaceuticals, Inc.

Financial Advocates Investment Management has acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, as stated in their recent filing with the Securities and Exchange Commission. The institution purchased 665 shares of the biopharmaceutical company, with an estimated value of around $474,000.

A variety of other institutional investors and hedge funds have also recently adjusted their holdings of REGN. For instance, Rakuten Securities Inc. boosted its investment in Regeneron Pharmaceuticals by 380.0% in the third quarter, now holding 24 shares worth $25,000 after adding 19 shares. Similarly, FSA Wealth Management LLC entered a new stake in Regeneron during the third quarter valued at $26,000, while Fairfield Financial Advisors LTD invested about $37,000. Truvestments Capital LLC also made a new investment of approximately $39,000, alongside Valley Wealth Managers Inc., who acquired shares worth about $49,000. Notably, institutional investors and hedge funds hold 83.31% of the company's shares.

Analysts Set Price Targets

Regeneron Pharmaceuticals has recently been analyzed by various financial experts. For example, UBS Group downgraded the stock from a "buy" rating to a "neutral" rating, lowering their price target from $1,130.00 to $738.00. Meanwhile, Royal Bank of Canada adjusted their price target from $1,260.00 to $1,215.00 while maintaining an "outperform" rating. Bank of America reaffirmed an "underperform" status with a target of $565.00. Additionally, Evercore ISI revised their target from $1,250.00 to $1,175.00 while keeping an "outperform" designation. Canaccord Genuity Group started following Regeneron with a "hold" rating and a price target of $165.00. In total, one analyst has issued a sell rating, six have a hold, seventeen have a buy, and two have a strong buy rating. Current data from MarketBeat indicates that the stock is viewed as a "Moderate Buy" with an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

As of the most recent trading session, Regeneron Pharmaceuticals shares opened at $710.00. The company boasts a market capitalization of $78.02 billion, with a price-to-earnings ratio of 18.55 and a price-to-earnings-growth ratio of 2.38. It has a low debt-to-equity ratio of 0.09, a quick ratio of 4.46, and a current ratio of 4.73. The 50-day moving average is $715.81, with a 200-day moving average at $911.09. The stock has recorded a 52-week low of $642.00 and a high of $1,211.20.

Quarterly Earnings Report

On February 4th, Regeneron Pharmaceuticals announced their quarterly earnings, revealing an earnings per share (EPS) of $12.07, which surpassed the consensus estimate of $11.21 by $0.86. The revenue for the quarter reached $3.79 billion, exceeding analyst projections of $3.76 billion. The company reported a net margin of 31.07% and a return on equity of 16.32%. Quarterly revenue grew by 10.3% compared to the same quarter the previous year. Analysts predict an EPS of approximately 36.67 for the current year.

Dividend Announcement

Regeneron Pharmaceuticals has also disclosed a quarterly dividend, which is set for distribution on March 20th. Shareholders recorded on February 20th will receive a dividend of $0.88 per share, translating to an annualized dividend of $3.52, leading to an approximate dividend yield of 0.50%. The ex-dividend date is also set for February 20th.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is engaged in the discovery, invention, development, manufacturing, and commercialization of medicines aimed at treating a variety of diseases worldwide. Their product lineup includes EYLEA, an injection used for treating conditions like wet age-related macular degeneration, diabetic macular edema, and more.

investment, shares, Regeneron